Quantitative imaging for <sup>177</sup>Lu-PSMA treatment response monitoring and dosimetry.
Ontology highlight
ABSTRACT: PSMA-targeted radiopharmaceutical therapy is an established treatment option for metastatic castration-resistant prostate cancer (mCRPC). However, response rates and duration using 177Lu-PSMA-617 vary considerably between patients. Quantitative 177Lu SPECT imaging is one approach that may be leveraged to more closely monitor inter-cycle response, as well as patient-specific absorbed doses. In this work, we describe our experience implementing quantitative imaging throughout the course of 177Lu-PSMA treatment, including serial SPECT imaging to monitor response and for individualized dosimetry. We also describe our imaging protocols and dose calculation workflows for 3D voxelized patient-specific organ and tumor dosimetry, including a review of the current la
SUBMITTER: Meyer C
PROVIDER: S-EPMC11440845 | biostudies-literature | 2023
REPOSITORIES: biostudies-literature
ACCESS DATA